A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
Key facts
- Where
- Baton Rouge, Birmingham, Boca Raton, Boynton Beach, Columbus, Coral Gables, Dallas, Detroit, Fountain Valley, Fremont, Glenn Dale, Houston, Huntington Beach, Indianapolis, Los Angeles, Marietta, Montgomery, New York, Plano, Portland, Portsmouth, Rockville, San Antonio, Sandy Springs, Spokane, Thousand Oaks, West Dundee, and West Palm Beach, United StatesSee the 33 sites
- Phase
- Phase 3
Where in United States
- DelRicht ResearchBaton Rouge, United StatesNo longer taking part
- University of Alabama At Birmingham Hospital-Whitaker ClinicBirmingham, United StatesNo longer taking part
- Skin Care Research, LLCBoca Raton, United StatesNo longer taking part
- Total Vein and Skin LLCBoynton Beach, United StatesNo longer taking part
- Remington Davis Clinical ResearchColumbus, United StatesNo longer taking part
- Driven Research LLCCoral Gables, United StatesNo longer taking part
- Florida Academic Centers Research and Education, LLCCoral Gables, United StatesNo longer taking part
- Pediatric Skin Research LLCCoral Gables, United StatesNo longer taking part
- Dermatology Treatment and Research CenterDallas, United StatesNo longer taking part
- Henry Ford Health SystemDetroit, United StatesNo longer taking part
- First Oc Dermatology Research IncFountain Valley, United StatesNo longer taking part
- Center For Dermatology Clinical Research, Inc.Fremont, United StatesNo longer taking part
- Callender Dermatology and Cosmetic CenterGlenn Dale, United StatesNo longer taking part
- Heights Dermatology and Aesthetic CenterHouston, United StatesNo longer taking part
- University of Texas, Md Anderson CancerHouston, United StatesNo longer taking part
- Marvel Clinical Research, LLCHuntington Beach, United StatesNo longer taking part
- Indiana University School of Medicine Iusm IndianapolisIndianapolis, United StatesNo longer taking part
- Dermatology Research AssociatesLos Angeles, United StatesNo longer taking part
- Vitiligo & Pigmentation Institute of Southern CaliforniaLos Angeles, United StatesNo longer taking part
- Dermatology and Surgery Specialists of North AtlantaMarietta, United StatesNo longer taking part
- C2 Research Center, LLCMontgomery, United StatesNo longer taking part
- Weill Cornell Medical CollegeNew York, United StatesNo longer taking part
- Innovative Dermatology: Legacy Medical VillagePlano, United StatesNo longer taking part
- Oregon Medical Research Center PCPortland, United StatesNo longer taking part
- Allcutis Research, LlcPortsmouth, United StatesNo longer taking part
- Aesthetic and Dermatology CenterRockville, United StatesNo longer taking part
- Dermatology Clinical Research Center of San AntonioSan Antonio, United StatesNo longer taking part
- Texas Dermatology and Laser SpecialistsSan Antonio, United StatesNo longer taking part
- Advanced Medical Research, PC.Sandy Springs, United StatesNo longer taking part
- Premier Clinical ResearchSpokane, United StatesNo longer taking part
- Clinical Trials Research InstituteThousand Oaks, United StatesNo longer taking part
- Dundee DermatologyWest Dundee, United StatesNo longer taking part
- Metabolic Research Institute, IncWest Palm Beach, United StatesNo longer taking part
Trial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT06113471EU 2023-506011-18-00
- Record updated
- 31 March 2026
- Original description
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Inclusion: Aged ≥ 18 years; Clinical diagnosis of nonsegmental vitiligo and meet the following:; T-BSA ≥ 5%; T-VASI score ≥ 4; F-BSA ≥ 0.5%; F-VASI score ≥ 0.5; Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit; Willingness to avoid pregnancy or fathering children.
Exclusion: Use of laser or phototherapy within 8 weeks and dihydroxyacetone within 4 weeks prior to Day 1; Spontaneous and significant repigmentation within 6 months prior to screening; Other forms of vitiligo or skin depigmentation disorders; History of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo; Evidence of infection with TB, HBV, HCV or HIV; History of failure to JAK inhibitor treatment of any inflammatory disease; Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or recurrent dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies; Laboratory values outside of the protocol-defined ranges; Other protocol-defined Inclusion/Exclusion Criteria may apply; Clinically significant abnormal TSH or free T4 at screening; Current or past use of the depigmenting agent monobenzyl ether of hydroquinone including Benoquin®; Women who are pregnant, considering pregnancy, or breast feeding.